Certificates of Analysis (COA) and Material Safety Data Sheets (MSDS) are available upon request to support institutional compliance across EU jurisdictions
Contact us today to schedule your free consultation with a cosmetic physician who specializes in laser treatments
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Healthcare providers considering clinical use of these peptides must ensure compliance with applicable federal, state, and local regulations
While it is not a controlled substance, and its use is common in clinical and home care settings, federal law mandates that it be labeled and sold as Rx only. Always obtain bacteriostatic water from a licensed and reputable source, and use it strictly as directed under medical guidance
Additional analysis explored the interaction between BPC 157 and several neurotransmitter and signaling systems, including dopaminergic, nitric oxide, prostaglandin, and somatosensory pathways